Network exposure 500 varieties will be collected! 3 years to complete a number of heavy biological drugs, insulin selected.

Wen/Linan In recent days, the industry has frequently flowed out of the relevant departments on Friday (July 24) to carry out the main points of the national collection meeting.
the content of the network related to the future national collection of covered varieties, as well as provincial collection of key tasks, as well as the third batch of national collection of the latest news.
Specific points are as follows: in 2013 to complete 500 varieties of collection network transmission content pointed out that the future volume procurement will be national, provincial and municipal coverage;
revealed that the National Health Insurance Administration requires that the first 80 percent of the first 80 percent of the drug about 500, each place can be determined according to the specific situation, specifically in 2021 to cover 250, in 2022 to full coverage.
not carried out in the country, it will be carried out by provincial organizations.
range of products, including uns evaluated products, large clinical sales, generic drugs more than three.
This means that the volume of procurement will bloom throughout the country, and by the local collection of varieties, it is very likely to be included in the national collection, even if temporarily not included, once the lowest price of the national linkage, for enterprises is also a big impact, clinical use of large, high amount of varieties in the future will be "one can not be less" into the collection catalog.
Previous documents have mentioned that the pilot provinces of comprehensive medical reform should take the lead in the procurement of drugs not included in the national collection by the end of September, and this document directly requires that all provinces be carried out in this year, the second half of the provincial collection is expected to be one of the important points of view.
3 years will be collected 500 varieties reference from Insight database 02 wolf came! Biopharmaceuticals and insulin are among the 500 varieties to be collected within 3 years, covering biopharmaceuticals and insulin.
the biological drugs in favor of toushima resistance, qutojuma, are Roche's heavy tumor drugs.
at present, there are many domestic enterprises layout of the two drugs biosynchric drug pipeline.
February 2019, Fuhong Hanlitoxi anti-injection liquid was approved for the market, becoming the first domestic bioseal drug.
In the competition for research and development of ritocym-resistant drugs, in addition to Fuhong Hanxuan, there are Xinda Bio, Shenzhou Cell Engineering, and on July 9 this year, the listing application for Fuhong Hanyu Quto-Zhu anti-biosycellular drugs has been changed to "in the approval", is expected to be approved for listing, becoming the first Quto-Zhu monobio-similar drugs.
According to media statistics, there are more than 10 pharmaceutical companies in China are developing Quto zhuma resistance, there are 7 pharmaceutical companies into phase III clinical, involving Zheng Datianqing, Hualan gene, Haizheng Pharmaceuticals, Jiahe biological, Anke biology and so on.
The list also includes several insulin varieties, such as essential protein biosynthetic human insulin (30R) injection type, sperm protein biosynthetic human insulin (50R) injection type, meningo insulin injection type, endo-insulin injection type, recombinant Insulin glycerin injection type, sperm protein zinc recombinant human insulin (70/30) injection, refined protein zinc recombinant insulin (25R) injection type, refined zinc recombinant insulin (50R) injection type.
, refined protein biosynthetic human insulin belongs to the second generation of insulin products.
insulin, tet insulin, recombinant insulin and other insulin products belong to the third generation.
data from key urban sample hospitals in the 100-meter in-network show that the current insulin market in China is dominated by the third generation of insulin, accounting for more than 80% of the total, and the rest is occupied by the second generation of insulin.
overall, the insulin market is mainly occupied by Noor and Nord, Sanofi, Lilly, market share of more than 80%, three generations of insulin insulin only slightly higher localization of insulin glycerol, but only 25%.
with the domestic three generations of insulin has been approved for listing, as well as the promotion of production procurement, the process of domestic substitution is expected to accelerate.
the above-mentioned varieties involved in the main domestic production enterprises are GanLi Pharmaceuticals, Thua Dongbao, Federal Pharmaceuticals and so on.
with the release of the catalogue, this means that biopharmaceuticals and insulin are being collected, not just a gust of wind, the wolf is really coming.
addition, the catalog also has 14 varieties in last year's first batch of national focus on monitoring rational drug catalog.
is mainly neurooxidine sodium injection type, Orasitan oral dosage form and injection type, prostatil injection type, quercetin hydrolytic hydrolytic injection type, compound coenzyme injection type, Dansanchuan -pyridine injection, conversion Glycoenolyte injection type, thymus perpetide injection type, Ida Lafun injection type, bone peptide injection type, encephaloprotein hydrolyte injection type, ribonucleic acid injection type, Changchun cetin injection type, calf blood deprotein extract injection type.
the network also pointed out that provinces do not worry about flow mark, flow mark products reported to the National Health Insurance Administration in a timely manner, will further study the reasons.
can't tell which provincial collection the above varieties will appear in.
With the development of belt procurement, China's generic enterprises profits are constantly compressed, the future needs pharmaceutical companies in the control of costs at the same time to ensure sales volume, with the integrated production line of API enterprises in the bargaining environment advantages highlighted.
with the variety coverage of more and more, the old pharmaceutical market pattern will be broken, the entire industry to speed up the shuffle.
03 The third batch of national mining rules published at the end of this month, said that the third batch of national mining rules are basically finalized, is expected to open on August 18, the end of July issued implementation plans and rules, the rules will adopt the second batch of national rules, such as 1.8 times the fuse mechanism and a 50% reduction in price.
, the purchase volume and the highest effective declared price of the product have come out, and will also increase the mechanism for the retention of health insurance fund balances.
Sina Pharmaceuticals inquired about the second batch of national collection announcement, the rules show that: the proposed selection of enterprises to determine the criteria for the finalist enterprise prices meet one of the following conditions, to obtain the proposed selection qualification: 1. " 1.8 times the unit 2.8 times the 2.8 times 2." Unit declared price "decreased by 50.00%;3." Units can be available for a 2000 yuan price of 0.1000 yuan.
time interval between the third batch and the second batch is six months, it is not surprising to extend some of the rules.
, from the 4 plus 7 pilot to the third batch, with volume procurement varieties continue to expand, the rules are also constantly improving, drug belt volume procurement has been written into the key tasks of medical reform, it is expected that the volume procurement mechanism will only continue to improve.
In addition, the content of this outflow also mentioned the mechanism to increase the balance of the health insurance fund retention, before similar rules exposed such as the requirement is "such as the amount of 1 million tablets, requiring the completion of 60%, if the hospital completed more than 600,000 tablets, not more than 1 million tablets, savings part of the incentive hospital half, more than 1 million pieces of cancellation incentives;
"Last year, in the pilot of 4-7 urban belt procurement, Dalian in the establishment of collection and collection implementation rules, one of which is to improve the balance retention mechanism, "medical institutions due to the standardized use of selected varieties and the completion of the use of the part to reduce the expenditure of the medical insurance fund, medical institutions can be retained, and in accordance with the relevant provisions can be used for medical personnel's compensation expenses, in order to mobilize the enthusiasm of medical personnel."
" third batch of countries to increase the mechanism of medical insurance fund balance retention, I do not know whether will refer to the practice of pilot cities.
we will continue to pay attention.
.